(Q46921390)

26 December 2017

title

Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells (English)

1 reference

26 December 2017

1 reference

1 reference

5

1 reference

26 December 2017

David Fulton

7

object named as

David Fulton

1 reference

26 December 2017

author name string

Amy K Banes-Berceli

1

1 reference

26 December 2017

Sean Shaw

2

1 reference

26 December 2017

Guochuan Ma

3

1 reference

26 December 2017

Michael Brands

4

1 reference

26 December 2017

David M Stern

6

1 reference

26 December 2017

R William Caldwell

8

1 reference

26 December 2017

Mario B Marrero

9

1 reference

26 December 2017

publication date

31 January 2006

1 reference

26 December 2017

American Journal of Physiology - Renal Physiology

published in

1 reference

26 December 2017

volume

291

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

F116-21

1 reference

26 December 2017

Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose.

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

HDL as a target in the treatment of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

A systematic review of drug therapy to delay or prevent type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

Antioxidant Therapy in Diabetic Complications: What is New?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00502.2005

10.1152/AJPRENAL.00502.2005

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16449352

1 reference

26 December 2017